Genetic Testing Firm GeneDx Reports Narrower Q3 Loss As Revenues Surge, Lifts Annual Guidance

GeneDx stock rises as Q3 results beat expectations with EPS loss improvement, 44% revenue growth to $76.87M, and 77% increase in test revenue.

read more

Leave a Reply

Your email address will not be published. Required fields are marked *